Abstract
Since the beginning of the HIV epidemic almost 70 million people have been infected with HIV. It is estimated that 42 million people are currently living with HIV/AIDS. The spread of HIV continues throughout the world and current estimates indicate that in 2002, 5 million people were newly infected with HIV and 3 million people died. Current treatments employ a combination of therapeutic agents that target the viral reverse transcriptase and protease enzymes and viral entry. However the clinical benefit of these agents is often limited due to issues of regimen compliance, significant side effects, and the emergence of viral strains that are drug resistant. The introduction of novel agents that interfere with alternate stages in the viral life cycle represent potential solutions to these problems. The integration of the HIV genome into the cellular chromosome, a process catalyzed by the viral enzyme integrase, has been shown to be essential for viral replication. Since HIV integrase has no direct cellular counterpart it presents itself as an attractive target for therapeutic intervention. This review summarizes recent and promising developments both in the HIV integrase field and the global quest for therapeutically useful inhibitors of HIV integrase.
Keywords: hiv-1 Integrase, aids, chemotherapeutics, cellular chromosome, hiv genome
Current Topics in Medicinal Chemistry
Title: HIV-1 Integrase: A Target for New AIDS Chemotherapeutics
Volume: 4 Issue: 9
Author(s): Neville J. Anthony
Affiliation:
Keywords: hiv-1 Integrase, aids, chemotherapeutics, cellular chromosome, hiv genome
Abstract: Since the beginning of the HIV epidemic almost 70 million people have been infected with HIV. It is estimated that 42 million people are currently living with HIV/AIDS. The spread of HIV continues throughout the world and current estimates indicate that in 2002, 5 million people were newly infected with HIV and 3 million people died. Current treatments employ a combination of therapeutic agents that target the viral reverse transcriptase and protease enzymes and viral entry. However the clinical benefit of these agents is often limited due to issues of regimen compliance, significant side effects, and the emergence of viral strains that are drug resistant. The introduction of novel agents that interfere with alternate stages in the viral life cycle represent potential solutions to these problems. The integration of the HIV genome into the cellular chromosome, a process catalyzed by the viral enzyme integrase, has been shown to be essential for viral replication. Since HIV integrase has no direct cellular counterpart it presents itself as an attractive target for therapeutic intervention. This review summarizes recent and promising developments both in the HIV integrase field and the global quest for therapeutically useful inhibitors of HIV integrase.
Export Options
About this article
Cite this article as:
Anthony J. Neville, HIV-1 Integrase: A Target for New AIDS Chemotherapeutics, Current Topics in Medicinal Chemistry 2004; 4 (9) . https://dx.doi.org/10.2174/1568026043388448
DOI https://dx.doi.org/10.2174/1568026043388448 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
Addressing the Most Common Causes of Death with Niacin/NAD and Inositol Polyphosphates
The most common causes of death in the world are cardiovascular disease (CVD) and cancer. These are perhaps best addressed by reducing lipodystrophy and blockages with niacin and inositol polyphosphates (e.g., IP6+inositol) respectively when addressing CVD. Niacin serves as a vitamin by virtue of its role as a skeletal precursor ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Promising Anti-Cancer and Anti-Oxidant Agents Based on the Pyrrole and Fused Pyrrole: Synthesis, Docking Studies and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Hydrogen Gas Therapy: From Preclinical Studies to Clinical Trials
Current Pharmaceutical Design Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Computational Approaches on Angiotensin Receptors and Their Ligands: Recent Developments and Results
Current Medicinal Chemistry The Uses of Dimedone for the Synthesis of Thiophene, Thiazole and Annulated Derivatives with Antitumor, Pim-1 Kinase Inhibitions, PAINS Evaluations and Molecular Docking
Anti-Cancer Agents in Medicinal Chemistry Bile Acid Reabsorption Inhibitors (BARI): Novel Hypolipidemic Drugs
Current Medicinal Chemistry Interleukin-6 Inhibition and Lipoprotein(a): An Association Requiring More Research
Current Pharmaceutical Design Nef Surfaces: Where to Interfere with Function
Current HIV Research Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design A Case Study from the Chemistry Core of the Pittsburgh Molecular Library Screening Center: The Polo-like Kinase Polo-Box Domain (Plk1- PBD)
Current Topics in Medicinal Chemistry Promises of Molecular Pharmaceutics in the Development of Novel Drug Delivery Formulations
Current Drug Delivery Efficient Chemical Synthesis of a Scutellarein Derivative Containing Morpholine Ring
Letters in Organic Chemistry Recent Advances in the Discovery of Selective AMPA Receptor Positive Allosteric Modulators
Current Medicinal Chemistry <i>Larrea tridentata</i> and its Biological Activities
Current Topics in Medicinal Chemistry Efforts to Understand the Molecular Basis of Hypertension Through Drug:Membrane Interactions
Current Topics in Medicinal Chemistry Amide Derivatives of 2,3-diarylacrylophenone as Estrogen Receptor Binding Ligands
Medicinal Chemistry Microwave-Assisted Synthesis of Substituted 2,4-Diarylthiazoles and their Evaluation as Anticancer Agents
Letters in Drug Design & Discovery COVID-19: Pathogenesis and Pharmacological Basis for Use of Passive Antibody Therapy
Current Drug Therapy Metric Distances between Hippocampal Shapes Indicate Different Rates of Change over Time in Nondemented and Demented Subjects
Current Alzheimer Research The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews